High IL1R1 expression predicts poor survival and benefit from stem cell transplant in intermediate-risk acute myeloid leukemia from the Leucegene cohort.

Biomark Res · 2025 · PMC12548205 · PMID 41131586

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

only marginally significantp = 0.06so close (0.05 < p ≤ 0.1)

Among patients with FLT3 -ITD +, all patients benefited from HSCT irrespective of IL1R1 expression, although the benefit was only marginally significant in patients with IL1R1 low (HR for OS 0.41, p = 0.06).

also in 5,076 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.